NetworkNewsBreaks Archive - Page 1975 of 2081

ThursdayJun 22, 2017 1:39 pm

NetworkNewsBreaks – Moxian (NASDAQ: MOXC) Aims for $25M Revenues in 2018, Leverages High Gross Margin and Existing SME Customer Base in China’s O2O Market

Investors will find a high-risk/high-reward opportunity in China’s online-to-offline (O2O) marketplace through Moxian, Inc. (NASDAQ: MOXC), a development-stage company currently executing a marketing strategy of converting its two O2O platforms from unpaid to paid. Based in Shenzhen, China, Moxian has a gross margin of 77.4 percent, which is the second-highest among its significantly higher market cap competitors, according to a SeeThruEquity research report (http://nnw.fm/dee5W). “SeeThruEquity notes that MOXC believes it can achieve a revenue total of $25 million in 2018. The company anticipates revenue of $11 million in 2017. Key to achieving its profit goals is MOXC’s high profit margins…

ThursdayJun 22, 2017 1:38 pm

NetworkNewsBreaks – DelMar Pharmaceuticals (NASDAQ: DMPI) Shares Rise on IRB Approval for VAL-083 STAR-3 GBM Trial

DelMar Pharmaceuticals (NASDAQ: DMPI) shares are moving 21% higher today on news that the company has Institutional Review Board (IRB) approval to conduct its pivotal phase 3 study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (STAR-3). IRBs are required under FDA regulations to review all human subject research to guarantee that the rights and welfare of human subjects are protected at all times. The VAL-083 STAR-3 GBM trial and all relevant study related materials were critically examined by the leading independent institutional review board and approved without any modifications. "We are pleased to remain on track to open enrollment in this trial…

ThursdayJun 22, 2017 12:53 pm

NetworkNewsBreaks – Integral Technologies, Inc.’s (ITKG) ElectriPlast Conductive Plastic Chosen For Long-Term Deal By European Electric Car Maker

Integral Technologies (OTC: ITKG), together with its wholly owned subsidiary ElectriPlast Corp., reports that its ElectriPlast material has been selected by a leading European electric luxury SUV manufacturer for use in a high voltage connector. The order marks the company’s second ElectriPlast order so far this year and the first European automotive commercial order. The electric SUV is expected to make its European debut in late 2017, and the order will run through 2024. "We never waivered in our belief that there was tremendous potential in the automotive industry for conductive plastic and this is just another validation. Now that…

ThursdayJun 22, 2017 9:50 am

NetworkNewsBreaks – ORHub, Inc. (ORHB) Platform Featured in ‘Customer Stories’ Piece by Microsoft

Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) was recently highlighted as part of a customer story created by tech giant Microsoft (NASDAQ: MSFT) covering the Hoag Orthopedic Institute (HOI). The informative piece gives readers some insight into HOI’s efforts to advance orthopedic care, particularly as they relate to ORHub, an innovative surgical resource management solution running on the Microsoft Azure platform and accessible in the operating room using a Microsoft Surface device. “With ORHub, HOI is improving teamwork, automating manual processes, and better understanding resource allocation in its spinal surgeries,” the article reads. Richard Lee, MD, an orthopedic surgeon…

WednesdayJun 21, 2017 3:03 pm

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Discovery of Metabolic Inhibitor with Potential to Treat Pancreatic Cancer; Shares Rise

Shares of Moleculin Biotech (NASDAQ: MBRX) are up more than 30% after the company said that WP1234, a metabolic inhibitor, is a positive drug candidate to be studied for the potential to treat pancreatic cancer. Pancreatic cancer is still considered mostly untreatable, so any improvement in treating this disease could symbolize a significant clinical benefit. "We have identified possible new properties of our compound WP1234, a modification to WP1122. In pre-clinical testing, WP1234 has shown improved drug characteristics when compared with WP1122 and a 20 to 50-fold greater ability to kill pancreatic cancer cell lines when compared with traditional inhibitors…

WednesdayJun 21, 2017 3:00 pm

NetworkNewsBreaks – Grow Condos, Inc. (GRWC) Provides Positive Update on ‘Smoke on the Water’ at Lake Selmac

Grow Condos (OTCQB: GRWC) this morning provided an update on "Smoke on the Water" at Lake Selmac, the company’s resort designed to cater to and capitalize on the country's persistently increasing level of recreational marijuana acceptance. The company reports that the park is undergoing a series of alterations, including culturally diverse upgrades and added value services for patrons of the resort. Among the highlights of the park’s changing atmosphere are the delivery of its tee-pees for its Native American section, which also features yoga and other spiritually enhancing activities. "Smoke on the Water" has launched its own roll up development…

WednesdayJun 21, 2017 12:33 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 21, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: MBRX 28.31% – News: Reports discovery of metabolic inhibitor with potential to treat pancreatic cancer SHIP 15.94% – News: Posts new corporate presentation on its website PRGE 15.76% – News: Grupo subsidiary contracts to purchase a warehouse facility in Dallas, Texas SKYS 15.07% – News: Law firm notifies investors of a class action lawsuit CXRX 9.37% – News: Provides long-term growth strategy update BIOC 6.15% – News: Enters agreement with MediNcrease BDSI 5.77% –…

WednesdayJun 21, 2017 12:32 pm

NetworkNewsBreaks – Trevena, Inc. (NASDAQ: TRVN) Reiterated with “Buy” Rating at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $14 on shares of Trevena, Inc. (NASDAQ: TRVN) following the company’s recent management meetings. Among other highlights from the meetings, the analyst noted Trevena’s completion of pre-launch commercial activity. Trevena has completed interviews with around 140 pharmacy directors and 40 anesthesiologists regarding Olinvo. As for the investors' concerns regarding the launch of Olinvo in the U.S., the analyst believes it is worth launching and could be a product with peak year revenue in the range of $200 million-$300 million. For more information, visit www.trevena.com About Trevena Trevena, Inc. is…

WednesdayJun 21, 2017 12:30 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Axsome Therapeutics, Inc. (NASDAQ: AXSM)

Following Axsome Therapeutics, Inc.’s (NASDAQ: AXSM) appointment of Myrtle Potter to its board of directors, Aegis Capital reiterated its ‘Buy’ rating and price target of $20 on shares of the company’s stock. Calling the appointment “incrementally positive,” the analyst voiced confidence that the appointment of the former Genentech executive, specifically her experience in the commercialization process, adds value to Axsome’s board. For more information, visit www.axsome.com About Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsome’s product candidate…

WednesdayJun 21, 2017 11:29 am

NetworkNewsBreaks – ORHub, Inc. (ORHB) Announces Exercise Price for Series B and D Warrants

Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) today announced a $0.50 exercise price for all of its Series B and D warrants. Per this morning’s news release, the exercise price will commence immediately and remain in place until all of the related warrants have been exercised or have reached their expiration date, currently set at December 31, 2017. If all of the Series B and D warrants are exercised, the company estimates that it will receive more than $5.5 million in additional proceeds with which to fund the launch of its innovative software platform into hospital chains located throughout…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks